Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers

By Dias Maria   Carvalho Jesus   Rodrigues Debora   Graziani Silvia   Maranhão Raul  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 105-111

Springer Publishing Company

Access to resources Recommend Favorite

Neurological Monitoring of Neurotoxicity Induced by Paclitaxel/Cisplatin Chemotherapy

By Berger T.   Malayeri R.   Doppelbauer A.   Krajnik G.   Huber H.   Auff E.   Pirker R.  

European Journal of Cancer, Vol. 33, Iss. 9, 1997-08 ,pp. : 1393-1399

Elsevier

Access to resources Recommend Favorite

Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum

By du Bois A.   Luck H.J.   Buser K.   Meerpohl H.G.   Sessa C.   Klaassen U.   Meden H.   Bochtler H.   Diergarten K.  

European Journal of Cancer, Vol. 33, Iss. 3, 1997-03 ,pp. : 379-384

Elsevier

Access to resources Recommend Favorite

Efficacy of Intra-arterial Infusion Therapy Using a Combination of Cisplatin and Docetaxel for Recurrent Head and Neck Cancers Compared with Cisplatin Alone

By Yabuuchi H.   Kuroiwa T.   Tajima T.   Tomita K.   Ochiai N.   Kawamoto K.  

Clinical Oncology, Vol. 15, Iss. 8, 2003-12 ,pp. : 467-472

Elsevier

Access to resources Recommend Favorite

Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study

By Thigpen J.T.   Blessing J.A.   Olt G.   Lentz S.S.   Bell J.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 581-586

Elsevier

Access to resources Recommend Favorite